Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

14 mins

Emerging Cell Therapy Approaches in Relapsed/Refractory Acute Myeloid Leukaemia in Older Adults

Manan Shah, Nicholas Yuhasz, Hannah Choe

Acute myeloid leukaemia (AML) is a heterogeneous haematologic cancer associated with clonal expansion of myeloid blasts in the bloodstream, bone marrow and other tissues. AML is associated with blasts expressing various complex molecular and cytogenetic alterations, which play an important role in disease prognostication. The median age of AML diagnosis is 67 years with nearly […]

touchREVIEWS in Oncology & Haematology. 2025;21(1):1–6:Online ahead of journal publication

Supportive Cancer Care

< 1 min

Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Bernardo L Rapoport, Pere Gascon, Florian Scotte, Karin Jordan, Massimo Di Maio, Sussanne Borjeson, Sam H Ahmedzai

Published Online: Mar 16th 2018 European Oncology & Haematology, 2018;14(1):[Online only]

Quick Links:

Select a Section…

1. Article

2. Further Resources

3. Related Content

Article

The authors of the aforementioned article would like to make revisions to the labels in Figure 1 as shown below. The article has been corrected online.

Further Resources

15 mins

Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression

Joanna A Young, Antoinette R Tan

Chemotherapy-induced myelosuppression has long been considered a toxicity that limits the dose of cytotoxic agents, which contributes to significant morbidity and mortality.1 Sub-optimal dose intensity may decrease the efficacy of therapy, thereby compromising progression-free survival (PFS) and overall survival (OS) benefits.2 Chemotherapy-induced myelosuppression is often managed with granulocyte-colony stimulating factors (G-CSFs) and erythropoiesis-stimulating agents (ESAs) […]

touchREVIEWS in Oncology & Haematology. 2022;18(2):152-8 DOI: https://doi.org/10.17925/OHR.2022.18.2.152

Related Content in Supportive Cancer Care

Foreword - touchREVIEWS in Oncology & Haematology - VOLUME 18 ISSUE 1 - 2022

Welcome to the latest edition of touchREVIEWS in Oncology & Haematology. Despite the success of the human papillomavirus vaccination programme, cervical cancer remains one of the most common cancers in women, and advanced disease carries a poor prognosis. Lebreton et ...

Foreword - touchREVIEWS in Oncology & Haematology - VOLUME 17 ISSUE 2 - 2021

Shaji K Kumar

Welcome to the winter edition of touchREVIEWS in Oncology & Haematology. Despite the continued impact of the COVID-19 pandemic on cancer care, 2021 has seen important advances in many areas of oncology, which is reflected in our diverse range of articles. ...

touchREVIEWS in Oncology & Haematology - 2021;17(2):55

Foreword - touchREVIEWS in Oncology & Haematology - VOLUME 17 ISSUE 1 - 2021

Shaji K Kumar, Axel Merseburger

Welcome to the inaugral issue of touchREVIEWS in Oncology & Haematology (formerly Oncology & Hematology Review [US]), which aims to summarize the latest clinical data and provide practical advice to help busy physicians in their daily practice. As co-editors-in-chief of ...

touchREVIEWS in Oncology & Haematology. 2021;17(1):1-2

Cancer Nursing Deserves Better Recognition

Cancer is a growing problem that demands the best from all sectors of the global health workforce.1 Cancer nurses make up the largest proportion of this workforce and, as well as being responsible for direct care delivery, also aim to ...

European Oncology & Haematology, 2019:15(1):19–20 DOI: https://doi.org/10.17925/EOH.2019.15.1.19

The Impact of Biosimilars in Supportive Care in Cancer

Biosimilars, which are copies of patent-expired large-molecule biologic drugs (Table 1),1–8 offer the same rationale as generic drugs. They can give patients, hospitals and healthcare systems the opportunity to expand patient access to care and offer potential budget savings to reinvest (...

European Oncology & Haematology. 2018;14(1):20–32 DOI: https://doi.org/10.17925/EOH.2018.14.1.20

Exercise for Toxicity Management in Cancer—A Narrative Review

Forty percent of Americans will be diagnosed with cancer in their lifetimes.1 Due to continued advances in cancer detection and treatment, there are an unprecedented number of cancer survivors. In fact, the 5-year survival rate for all cancers has increased ...

Oncology & Hematology Review. 2018;14(1):28–37 DOI: https://doi.org/10.17925/OHR.2018.14.1.28

Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Despite the increasing availability of precision medicine and the recent introduction of immune checkpoint inhibitors in the treatment of many tumours, chemotherapy remains the standard of care for most patients with cancer. Chemotherapy-induced nausea and vomiting (CINV) is highly prevalent ...

European Oncology & Haematology, 2017;13(2):120–6 DOI: https://doi.org/10.17925/EOH.2017.13.02.120

Call for Submissions 2018

Dear Colleagues, European Oncology & Haematology is now accepting submissions to the Summer and Winter 2018 editions. European Oncology & Haematology aims to publish topical articles, which are chosen for their evaluation of current practices and research that directly affect practitioners ...

European Oncology & Haematology, 2017;13(2):101 DOI: https://doi.org/10.17925/EOH.2017.13.02.101

Call for Submissions

Dear Colleagues Oncology & Hematology Review (US) is now accepting submissions to the Spring and Fall 2018 editions. Oncology & Hematology Review (US) aims to provide practicing oncologists and hematologists with concise and timely articles that provide practical advice relevant to ...

Oncology & Hematology Review, 2017;13(2):75 DOI: https://doi.org/10.17925/OHR.2017.13.02.75

What Happens when the Cost of Cancer Care Becomes Unsustainable?

The estimated incidence of cancer increased by almost one third across Europe between 1995 and 2012, and this growth is predicted to continue.1,2 Compared with other diseases and disabilities, the lost years of life and productivity resulting from cancer represent a heavy ...

European Oncology & Haematology, 2017;13(2):108–13 DOI: https://doi.org/10.17925/EOH.2017.13.02.108

Can we Continue to Afford Access to Cancer Treatment?

Innovation in healthcare is highly beneficial from a patient perspective; however, the introduction of new drugs, often at high cost, is placing increasing pressure on many healthcare systems.1 As a result, these systems are facing a growing crisis of affordability, ...

European Oncology & Haematology, 2017;13(2):114–9 DOI: https://doi.org/10.17925/EOH.2017.13.02.114

Oncological Scenario in Developing Countries – Little Light at the End of Tunnel

The incidence and prevalence of most cancers is increasing worldwide because of the aging population, increased prevalence of established risk factors with urbanisation and economic development and changing social and demographic trends including late marriage and fewer child-births. Based on ...

European Oncology & Haematology, 2017;13(1):13–4

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Emerging Cell Therapy Approaches in Relapsed/Refractory Acute Myeloid Leukaemia in Older Adults

Conference Coverage

Learning Activities

Journals

Emerging Cell Therapy Approaches in Relapsed/Refractory Acute Myeloid Leukaemia in Older Adults

Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Article

This Content is for
Members Only

Further Resources

1. Download PDF

2. View Original

3. Get Permission

4. Share This

Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression

Foreword - touchREVIEWS in Oncology & Haematology - VOLUME 18 ISSUE 1 - 2022

Foreword - touchREVIEWS in Oncology & Haematology - VOLUME 17 ISSUE 2 - 2021

Foreword - touchREVIEWS in Oncology & Haematology - VOLUME 17 ISSUE 1 - 2021

Cancer Nursing Deserves Better Recognition

The Impact of Biosimilars in Supportive Care in Cancer

Exercise for Toxicity Management in Cancer—A Narrative Review

Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Call for Submissions 2018

Call for Submissions

What Happens when the Cost of Cancer Care Becomes Unsustainable?

Can we Continue to Afford Access to Cancer Treatment?

Oncological Scenario in Developing Countries – Little Light at the End of Tunnel

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Trending Topic

Connect With Us:

Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Article

This Content is forMembers Only

Further Resources

1. Download PDF

2. View Original

3. Get Permission

4. Share This

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Content is for
Members Only

This Functionality is for
Members Only